Literature DB >> 28579727

Immunotherapies in Late-Stage Development for Patients With Severe SLE and/or Lupus Nephritis.

Chris Fellner.   

Abstract

We review the immunomodulatory agents in development for systemic lupus erythematosus, a relatively uncommon disorder affecting women of childbearing age.

Entities:  

Year:  2017        PMID： 28579727      PMCID： PMC5440101     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  6 in total

Review 1.  Peptide-based approaches to treat lupus and other autoimmune diseases.

Authors:  Nicolas Schall; Nicolas Page; Christophe Macri; Olivier Chaloin; Jean-Paul Briand; Sylviane Muller
Journal:  J Autoimmun       Date:  2012-06-22       Impact factor: 7.094

2.  Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study.

Authors: 
Journal:  Arthritis Rheumatol       Date:  2014-11       Impact factor: 10.995

3.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.

Authors:  Charles G Helmick; David T Felson; Reva C Lawrence; Sherine Gabriel; Rosemarie Hirsch; C Kent Kwoh; Matthew H Liang; Hilal Maradit Kremers; Maureen D Mayes; Peter A Merkel; Stanley R Pillemer; John D Reveille; John H Stone
Journal:  Arthritis Rheum       Date:  2008-01

4.  Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody.

Authors:  Li Peng; Vaheh Oganesyan; Herren Wu; William F Dall'Acqua; Melissa M Damschroder
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 5.  Update on Biologic Therapies for Systemic Lupus Erythematosus.

Authors:  Helena Hiemisch Lobo Borba; Andreas Funke; Astrid Wiens; Shirley Ramos da Rosa Utiyama; Cássio Marques Perlin; Roberto Pontarolo
Journal:  Curr Rheumatol Rep       Date:  2016-07       Impact factor: 4.686

6.  Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial.

Authors:  Robert Zimmer; Hugo R Scherbarth; Oscar Luis Rillo; Juan Jesus Gomez-Reino; Sylviane Muller
Journal:  Ann Rheum Dis       Date:  2012-11-21       Impact factor: 19.103
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.